Drs. Taylor and Cox joining our esteemed advisory board both deepens our scientific expertise as well as broadens the diversity of voices shaping our technology so that it can best serve all of the communities looking to medical cannabis to improve their health and quality of life.”
SAN FRANCISCO (PRWEB) August 14, 2020
Cannformatics, an early stage biotech startup pioneering the use of metabolomics and AI to personalize medical cannabis treatments, today announced two new members to the company’s advisory board. The company welcomes nationally recognized board-certified emergency medicine physician Dr. Myiesha Taylor and University of California, San Francisco Assistant Professor Dr. Stephany Cox.
Dr. Taylor was recently named as one of Essence Magazine’s 50 Essential Heroes for her work in addressing COVID-19 healthcare disparities in underserved communities, she is also instrumental in the creation of the We Are Doc McStuffins movement and had the mother character named after her in Disney’s popular and historic show Doc McStuffins, for her work in championing black women around the world to pursue medical degrees. Dr. Cox is a pediatric neuropsychologist whose expertise includes neurodevelopmental disorders such as autism spectrum disorder and attention deficit/hyperactivity disorder, she is also Co-Director of the UCSF Healthy Hearts and Minds Program. Both Drs. Taylor and Cox will provide scientific review and high-level advice to Cannformatics’ management with regards to its upcoming autism pilot study as well as other R&D activities.
“Understanding cannabis’ impact on physiology and its connection to change in behavior is critical to removing stigma and creating broad acceptance of cannabis as a legitimate treatment option for the medical community,” said Cannformatics CEO Dr. Itzhak Kurek. “Cannformatics is at the forefront of identifying cannabis-responsive biomarkers found in saliva and applying them to personalized medical cannabis recommendations. Drs. Taylor and Cox joining our esteemed advisory board both deepens our scientific expertise as well as broadens the diversity of voices shaping our technology so that it can best serve all of the communities looking to medical cannabis to improve their health and quality of life.”
About Cannformatics, Inc:
Cannformatics is an early stage biotechnology startup focused on personalizing medical cannabis treatment through the identification and application of cannabis-responsive biomarkers found in saliva. The company’s mission is to deliver predictable and repeatable science-based medical cannabis recommendations to improve health and quality of life. Cannformatics’ early successes include identifying two cannabis-dependent biomarkers related to General Anxiety Disorder as part of its proof-of-concept. The company is now pursuing identifying biomarkers related to autism spectrum disorder in children. Learn more at http://www.cannformatics.com and follow us on Twitter @cannformatics. Cannformatics is headquartered in San Francisco, CA.
